Form 4: Xeris Biopharma Director Receives Equity Grant

Director Garheng Kong acquired 24,193 restricted stock units and 32,996 stock options as part of an annual incentive plan.

Summary

• Director Garheng Kong was granted 24,193 restricted stock units (RSUs) on June 4, 2026.
• Director Garheng Kong was granted 32,996 stock options with an exercise price of $6.15 per share.
• The equity awards vest in full on the earlier of June 4, 2026, or the date of the next annual meeting of stockholders.
• Following these transactions, the director's total beneficial ownership of common stock increased to 238,337 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard incentive structure under the company's 2018 Stock Option and Incentive Plan.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of options and vesting of RSUs.

Risks

• Market price volatility affecting the value of the granted options.
• Dependence on continued service for the vesting of equity awards.

Future Outlook

The equity grants are subject to vesting conditions tied to the director's continued service through the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biopharmaceutical sector to ensure long-term alignment with shareholder value creation.

Comparison to Industry Standards

• The use of RSU and option grants is consistent with standard compensation packages for board members in mid-cap biotech firms.
• Vesting schedules tied to annual meetings are common practice for director equity awards.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of options.

Next Steps

• Vesting of equity awards on the date of the next annual meeting of stockholders.

Key Dates

Keywords

Xeris Biopharma, XERS, Form 4, Insider Trading, Equity Compensation, Director Compensation